Menta Capital’s Aratana Therapeutics, Inc. PETX Stock Holding History

Menta Capital’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-20,293	Closed	-$73K	–	650
2019 Q1	$73K	Sell	20,293 -19,269	-49%	-$83.5K	0.03%	454
2018 Q4	$243K	Buy	39,562 +16,333	+70%	+$99.7K	0.09%	366
2018 Q3	$136K	Buy	+23,229	New	+$116K	0.05%	518

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Menta Capital's PETX Position: Q2 2019 in Review

Menta Capital sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 20,293 shares — an estimated $73K sold.

Menta Capital first reported a position in PETX in Q3 2018 and held it in 3 quarters. The position peaked at $243K in Q4 2018. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Menta Capital reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Menta Capital sold 20,293 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $73K.
Menta Capital first reported a position in Aratana Therapeutics, Inc. in Q3 2018 and held it in 3 quarters.
Menta Capital's Aratana Therapeutics, Inc. position peaked at $243K in Q4 2018.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Menta Capital's 13F filing for Q2 2019, filed 7 Aug 2019.